SARS-CoV-2 reinfection trends in South Africa: analysis of routine surveillance data

  title={SARS-CoV-2 reinfection trends in South Africa: analysis of routine surveillance data},
  author={J. R. C. Pulliam and Cari van Schalkwyk and Nelesh P. Govender and Anne von Gottberg and Cheryl Cohen and Michelle J. Groome and Jonathan Dushoff and K. Mlisana and Harry Moultrie},
Objective: To examine whether SARS-CoV-2 reinfection risk has changed through time in South Africa, in the context of the emergence of the Beta and Delta variants Design: Retrospective analysis of routine epidemiological surveillance data Setting: Line list data on SARS-CoV-2 with specimen receipt dates between 04 March 2020 and 30 June 2021, collected through South Africa's National Notifiable Medical Conditions Surveillance System Participants: 1,551,655 individuals with laboratory-confirmed… 
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa
Analysis of routine surveillance data from South Africa indicates that the Omicron variant of SARS-CoV-2 evades immunity from prior infection, and this variant does not fully evade vaccine-derived immunity, but only those privileged to have been vaccinated can benefit.
Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron
It is demonstrated that SARS-CoV-2 infection in children induces robust memory T cells and antibodies that persist for more than 12 months, but lack neutralizing activity against omicron.
Molecular and Clinical Investigation of COVID-19: From Pathogenesis and Immune Responses to Novel Diagnosis and Treatment
This review focuses on the recent and up-to-date knowledge on SARS-CoV-2 (Alpha to Omicron) origin and evolution, structure, genetic diversity, route of transmission, pathogenesis, new diagnostic, and treatment strategies, as well as the psychological and economic impact of COVID-19 pandemic on individuals and their lives around the world.
The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve, emerging novel variants with spike protein mutations. Although most mutations emerged in the SARS-CoV-2 genome
Covid-19: South Africa’s surge in cases deepens alarm over omicron variant
In the outbreak’s epicentre—Gauteng, the populous province that contains Pretoria and Johannesburg—74% of samples sequenced from the last three weeks of November involved the new variant. This
Humoral, Cellular and Cytokine Immune Responses Against SARS-CoV-2 Variants in COVID-19 Convalescent and Confirmed Patients With Different Disease Severities
Significant resistance of the delta and omicron variants to the humoral immune response generated by individuals who recently experienced COVID-19 is found and there was a significant correlation among disease severity, humoral immunity response, and specific cytokines/chemokine levels.
Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico
The vaccine was found to be safe and the higher doses tested were found to to be immunogenic when given intramuscularly or intranasally followed by intamuscular administration, providing the basis for further clinical development of the vaccine candidate.
How bad is Omicron? What scientists know so far.
It might take scientists weeks to paint a more complete picture of Omicron, and to gain an understanding of its transmissibility and severity, as well as its potential to evade vaccines and cause reinfections.
Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 S antibodies
Two doses of CoronaVac induces antibody titers against the SARS-CoV-2 ancestral strain which are lower in magnitude than those induced by the BNT162b2 vaccine, however, the response induced by CoronaVacs can be greatly potentiated with a heterologous booster scheme with BNT 162b2 or ChAdOx1 vaccines.


Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period January-May 2021
Substantial differences in dissemination of SARS-CoV-2 infection between different race groups and provinces are demonstrated, in patterns consistent with known differences in historically entrenched socio-economic status and housing conditions.
Quantifying the risk of SARS‐CoV‐2 reinfection over time
Data suggest that naturally acquired SARS‐CoV‐2 immunity does not wane for at least 10 months post‐infection, however, the applicability of these studies to new variants or to vaccine‐induced immunity remains uncertain.
Detection of a SARS-CoV-2 variant of concern in South Africa
A newly arisen lineage of SARS-CoV-2 is described that is defined by eight mutations in the spike protein, including three substitutions at residues in its receptor-binding domain that may have functional importance.
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
Sera from individuals having received one dose of Pfizer or AstraZeneca vaccines barely inhibited variant Delta, and it was found that variant Delta spread is associated with an escape to antibodies targeting non-RBD and RBD Spike epitopes.
Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
The BNT162b2 vaccine was shown to have 95% efficacy against coronavirus disease 2019 (Covid-19) and administration of a single dose is now being considered in Israel.
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.
The recent emergence of new SARS-CoV-2 variants B.2.1.351 and emergent variants13,14 with similar spike mutations present new challenges for mAb therapy and threaten the protective efficacy of current vaccines.
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.
Preliminary evidence that vaccines based on VOC sequences could retain activity against other circulating SARS-CoV-2 lineages is provided, with the observed effective neutralization of first wave virus by 501Y.V2 infection elicited plasma.
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
This study examined whether sera from recovered and naïve donors, collected before and after immunizations with existing messenger RNA (mRNA) vaccines, could neutralize the Wuhan-Hu-1 and B.1.